India to United States: Dexamethasone Export Trade Route

The India to United States Dexamethasone corridor is one of India's established pharmaceutical export routes, with 439 shipments documented worth a combined $90.2M USD. The route is dominated by DR REDDYS LABORATORIES LIMITED, which alone accounts for roughly 33% of all export value, reflecting the consolidated nature of India's dexamethasone manufacturing sector.

Across 35 active suppliers, the average shipment value stands at $205.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 72% of all shipments, consistent with dexamethasone's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 26.0%, placing it at rank #6 among India's top dexamethasone export destinations globally.

On the import side, key buyers of Indian dexamethasone in United States include DR REDDYS LABORATORIES INC, DR.REDDY'S LABORATORIES,INC, DR, REDDYS LABORATORIES, INC and 106 others. DR REDDYS LABORATORIES INC is the single largest importer with 24 shipments valued at $30.9M USD.

India's dexamethasone exports to United States are driven primarily by a handful of large-scale manufacturers. DR REDDYS LABORATORIES LIMITED with 22 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 35 active exporters signals a competitive but concentrated market — buyers in United States benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — DR REDDYS LABORATORIES LIMITED, DR.REDDY'S LABORATORIES LTD, SUN PHARMACEUTICAL INDUSTRIES LIMITED — together account for 76% of total trade value on this route. The average shipment value of $205.5K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension usp 7.5ml bottle and ciprofloxacin 0.3% and dexamethasone 0.1 , suggesting that buyers in United States tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, DR REDDYS LABORATORIES INC is the largest importer with 24 shipments worth $30.9M USD — representing 34% of all dexamethasone imports from India on this route. A total of 109 buyers are active on this corridor.